Deferasirox pharmacokinetics in patients with adequate versus inadequate response. - Wikidata - awgldk - TriplyDB

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

http://www.wikidata.org/entity/Q37414682

about

Deferasirox for managing iron overload in people with thalassaemia Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine Beta thalassemia major in a developing country: epidemiological, clinical and evolutionary aspects.An update on disordered iron metabolism and iron overload.Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.Iron in sickle-cell disease: what have we learned over the years?Deferasirox: pharmacokinetics and clinical experience.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Clinical pharmacology of deferasirox.Deferasirox nephrotoxicity-the knowns and unknowns.Deferasirox for managing iron overload in people with thalassaemia.Current recommendations for chelation for transfusion-dependent thalassemia.Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.How we manage iron overload in sickle cell patients.Role of pharmacogenetics on deferasirox AUC and efficacy.Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Deferasirox in Indian children with thalassemia major: 3 years experience.MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients.Clinical relevance of deferasirox trough levels in β-thalassemia patients.Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.Management of cardiac hemochromatosis.Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications

P2860

Q24203718-B9D44786-DA88-4A42-8D3D-55EE451A1AF0 Q35683841-DBE84F14-81BF-4EDE-B797-3344D02A9D01 Q36498403-8953BD28-8195-4084-85E9-09689F8BBB9A Q36555894-B5E31740-7C6A-44C4-A8C7-63FB725F123E Q37791615-CE413270-44B5-4E86-8808-D6931AE97F73 Q37809009-8DCF86F0-E58E-4948-A12F-C1B20A52E6DB Q37820936-88741D07-7AD4-472C-A928-D73A2B61E77E Q37969225-43780A76-0135-41C6-9F51-CEDB70507853 Q38219588-BA998ECE-D68B-4970-BBA1-8BF660FDBAF1 Q38226394-989C85A8-0979-4EFB-9411-5AEEC55BA6A4 Q38232442-9255DDF0-FC60-41E4-86F9-33B5CA3BD748 Q38624033-569B0729-8E25-4C59-9EAE-C5AC7E8D1DA0 Q38836184-1042D5BC-5EC4-4215-ACAC-58082ED24A37 Q38874222-5D90750A-9700-47F6-AF2B-BFDD50F7253D Q39179372-0BB35B17-A6D2-438B-9A22-E0C91E121109 Q39865051-7A5C0C01-D753-4D77-B6E4-7F83AEB4E4D6 Q40499884-7C74B1B5-64AB-407D-B0BB-354D52E70EAB Q40657471-F47FC68A-24FB-45F2-BB44-50E2E38D6C6F Q40762243-4EB8EE80-1B56-459B-8A95-D02AA95E864A Q41687355-3A0AF9FF-5141-4C41-B929-27B2EF42ABA8 Q43085663-C78C9892-0C0E-4613-AA58-8C92947EC168 Q47156081-1F861095-DA57-4C1A-8A1A-352A37B7751E Q48180147-9D5F5B1A-F1FC-4A7B-8567-0BBCAE832EB4 Q48263712-816CEABD-EF8B-496A-A516-7AD4C05DC6B2 Q55230811-85F8EE1C-CD20-4F1D-9253-EA1B42198C50 Q58701095-F3928D6C-3096-4F4F-B9BC-8D06B93D131B

P2860

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

http://www.wikidata.org/entity/Q37414682

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

@en

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

@nl

type

label

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

@en

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

@nl

prefLabel

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

@en

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

@nl

P1433

Q37414682-78900794-DCA6-4C85-B1F8-1EF81CE5FEA1

P1476

Q37414682-C68E7C06-5364-476A-ABB1-2532DC2CF25A

P2093

Q37414682-2339087E-6C04-4471-818A-25DE4CF178B3

Q37414682-26595F52-CC6B-40C7-8728-2C814ADBD133

Q37414682-3B3F8120-F195-4FF5-A831-69131810CE49

Q37414682-5D18B6A2-57B7-460F-A1AB-7BE7331EF38C

Q37414682-A7C619D2-58E9-4E6C-A6D1-07910D0F2E71

Q37414682-AFD38268-F469-422C-87E9-B84A4E35555A

Q37414682-CE202790-7BAB-4ED7-9D2C-44D0131C2453

Q37414682-DABAA8AF-35E6-412F-89EE-1A31D842E43F

Q37414682-DC593F27-7EB7-4218-9128-B60425E64DF1

Q37414682-F6EEA447-165B-4F93-8782-7A5AFCFD572A

P2860

Q37414682-079F635A-077B-4F77-ACF8-1E7AD1F50084

Q37414682-2D8B88C8-D0F0-4AE1-8FF7-E59DA1A1CE6F

Q37414682-512ACB29-B561-4348-8362-F36779EDCBA5

Q37414682-557AE1B1-CA29-46F9-BBD5-F9DEE401F69E

Q37414682-8C5BE04E-8324-4326-899D-83B12A2DF410

Q37414682-8E908615-BA6C-452C-9325-EFEEDF5F319A

Q37414682-A5FBB8FF-AE45-45D0-8AD0-01673A39B43B

Q37414682-B61E161B-7FE7-44F2-AC04-2BDB2E6D0DAE

Q37414682-BE74676C-BCA9-4911-9649-A65CCFC6511A

Q37414682-C7A58390-3238-4B0A-9FD8-3F5D7CF4E9C3

P304

Q37414682-65DEFC7A-2F42-4103-B7BC-C40AD7E742B7

P31

Q37414682-061D0736-F981-4212-AC48-18C0B1DAF2E6

P356

Q37414682-BBBED88E-BB03-4B89-BFA2-3D40D1039A3D

P407

Q37414682-887460AC-F793-4F0F-91AD-1A1A5050039C

P433

Q37414682-0C793E36-4DBA-49AC-8633-51184A689005

P478

Q37414682-A554129D-298C-4048-91D5-A124FF593DD8

P577

Q37414682-71EEF00D-CE8C-41CC-A7FB-C591724D5EE6

P5875

Q37414682-3DE67843-A0A5-4390-B8C5-7EBB5C67B532

P698

Q37414682-67095420-8711-464B-8054-550E6A78EC7F

P921

Q37414682-9E7B8196-DA2D-4E29-A03D-6191C94E2FBF

P932

Q37414682-5A7F2AAB-2B1B-4631-8CC2-88F142A23941

P356

BLOOD-2009-05-222729

P1433

P1476

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

@en

P2093

Amber Lynn Smith

http://www.w3.org/2001/XMLSchema#string

Anke K Bergmann

http://www.w3.org/2001/XMLSchema#string

Carole Paley

http://www.w3.org/2001/XMLSchema#string

Deborah Chirnomas

http://www.w3.org/2001/XMLSchema#string

Ellis J Neufeld

http://www.w3.org/2001/XMLSchema#string

Frederick D Grant

http://www.w3.org/2001/XMLSchema#string

Jennifer Braunstein

http://www.w3.org/2001/XMLSchema#string

Luis Pereira

http://www.w3.org/2001/XMLSchema#string

Michael Shannon

http://www.w3.org/2001/XMLSchema#string

Yaron Finkelstein

http://www.w3.org/2001/XMLSchema#string

P2860

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

Treatment of Cooley's anemia.

Hb Dartmouth [alpha66(E15)Leu-->Pro (alpha2) (CTG-->CCG)]: a novel alpha2-globin gene mutation associated with severe neonatal anemia when inherited in trans with Southeast Asian alpha-thalassemia-1.

[Phase III multi-center clinical study on 99mTc-GSA, a new agent for functional imaging of the liver]

Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.

P304

4009-4013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-05-222729

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26783456

http://www.w3.org/2001/XMLSchema#string

P698

19724055

http://www.w3.org/2001/XMLSchema#string

P921

P932

2774541

http://www.w3.org/2001/XMLSchema#string